01—Abstract
Summary
Summary of the 8-K filed April 24, 2024. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific reported first-quarter 2024 results that were mixed: revenue declined 3% year over year to $10.34 billiona, with organic revenue down 4% and Core organic revenue down 3%.
Profitability held up better than the top line. GAAP diluted EPS rose 4% to $3.46b, GAAP operating margin expanded to 16.1% from 14.6%, and adjusted EPS increased 2% to $5.11 with adjusted operating margin at 22.0%. Free cash flow more than tripled to $908 million from $277 million, driven by higher operating cash flow of $1.25 billion.
The company raised its low end of full-year 2024 revenue guidance to $42.3 to $43.3 billionc (previously $42.1 to $43.3 billion) and raised its adjusted EPS guidance to $21.14 to $22.02 (previously $20.95 to $22.00). The raise is modest, and management attributed it to stronger operational performance. Capital deployment was active: the company repurchased $3.0 billion of stock and increased its dividend by 11%.
Cash and cash equivalents fell to $5.5 billiond from $8.1 billion, partly because of $1.76 billion in investment purchases and the buybacks, while total debt rose to roughly $35.6 billion from $34.9 billion after a $1.2 billion debt issuance. The weakest area was Life Sciences Solutions, where revenue fell about 12.5% to $2.29 billion, although segment margin expanded to 36.8% from 32.0%.
Analytical Instruments declined about 2%, Specialty Diagnostics was flat, and Laboratory Products and Biopharma Services was roughly flat to slightly down. The filing also references the pending acquisition of Olink, and investors will likely focus on how that deal affects leverage and growth in future periods.
02—Key points
Key Highlights
- Q1 2024 revenue of $10.34 billion fell 3% year over year; organic revenue declined 4% and Core organic revenue declined 3%, with COVID-19 testing a 1-point drag.
- GAAP diluted EPS rose 4% to $3.46 and GAAP operating margin expanded 150 basis points to 16.1%, with lower restructuring and amortization costs contributing.
- Adjusted EPS increased 2% to $5.11 and adjusted operating margin reached 22.0%, up from 21.8%, despite lower adjusted operating income of $2.28 billion versus $2.33 billion.
- Free cash flow nearly tripled to $908 million from $277 million, with operating cash flow of $1.25 billion versus $729 million a year earlier.
- Full-year 2024 guidance was modestly raised: revenue to $42.3 to $43.3 billion and adjusted EPS to $21.14 to $22.02.
- The company repurchased $3.0 billion of common stock in the quarter and raised its dividend by 11%.
- Life Sciences Solutions revenue fell about 12.5% to $2.29 billion, while its segment margin improved to 36.8%; the pending Olink acquisition is referenced in the filing.
03—Questions
Frequently Asked Questions
Why did revenue decline in Q1 2024 if the company is described as delivering strong results?
Revenue fell 3% to $10.34 billion, with organic revenue down 4%. The decline was concentrated in Life Sciences Solutions (down roughly 12.5%), where demand for certain products weakened, and COVID-19 testing was a further drag of about 1 percentage point. Management emphasized profitability and cash generation, which improved despite the top-line decline.
Did Thermo Fisher change its 2024 outlook?
Yes, modestly. Revenue guidance now ranges from $42.3 to $43.3 billion, versus the prior $42.1 to $43.3 billion, so only the low end moved up. Adjusted EPS guidance rose to $21.14 to $22.02 from $20.95 to $22.00. The changes are incremental, and management attributed them to stronger operational performance.
How is the company using its cash, and how has its balance sheet changed?
In Q1 the company repurchased $3.0 billion of stock, paid $135 million in dividends, and bought $1.76 billion of investments, which moved into short-term investments. It also issued $1.2 billion of new debt. Cash and equivalents fell to $5.5 billion from $8.1 billion, and total debt (short-term plus long-term obligations) rose to about $35.6 billion from $34.9 billion.
Are GAAP and adjusted results telling the same story?
Largely, though the gap matters. GAAP EPS grew 4% to $3.46, while adjusted EPS grew 2% to $5.11. Adjustments mainly exclude acquisition-related intangible amortization of $551 million, which is a large non-cash charge, along with restructuring and acquisition costs. Investors should weigh both measures, since the adjusted figures exclude recurring acquisition amortization that reflects past deal activity.
What does the pending Olink acquisition mean for investors?
The filing references the pending acquisition of Olink, which is being pursued through a tender offer by a Thermo Fisher subsidiary. The press release does not quantify its financial impact in this filing. Investors should review the tender offer materials and subsequent filings for terms, financing, and expected contribution to revenue and earnings.
04—Continue